SEC Form 4 · accession 0001552781-16-001820
MACROGENICS INC · MGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon Marc Wigginton
Officer — Sr VP Clinical Dev & CMO
Period of report
Jul 1, 2016
Accepted (ET)
Jul 6, 2016 · 8:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001125345
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 1, 2016 | M | 5,000 | $4.70 | A | 5,000 | D | |
| Common StockF1,F2 | Jul 1, 2016 | S | 5,000 | $27.22 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $4.70 | Jul 1, 2016 | M | 5,000 | D | Jan 18, 2014 | Jul 18, 2023 | Common Stock | 5,000 | 55,254 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This transaction was executed in multiple trades at prices ranging from $26.805 to $27.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.